Relationship Between Body Mass Index and Serum Testosterone Concentration in Patients Receiving Luteinizing Hormone-releasing Hormone Agonist Therapy for Prostate Cancer - 21/04/13
Reprint requests: André N. Vis, M.D., Ph.D, F.E.B.U., Department of Urology, VU University Medical Center, Room 4F027, P.O. Box 7057, Amsterdam 1007 MB, The Netherlands.Abstract |
Objective |
To evaluate the relationship between the body mass index (BMI) and serum testosterone concentrations in men receiving luteinizing hormone-releasing hormone (LHRH) agonist therapy for prostate cancer.
Materials and Methods |
A total of 66 white men were included in the present study. All subjects had received LHRH agonist therapy for ≥3 months. The BMI was calculated, and the subjects were classified as normal weight (i.e. BMI <25 kg/m2), overweight (BMI 25-30 kg/m2), or obese (BMI >30 kg/m2). The serum testosterone concentration was determined using the highly sensitive isotope dilution-liquid chromatography-tandem mass spectrometry technique. The sex hormone-binding globulin level was determined using an immunometric assay, and the free serum testosterone concentration was calculated.
Results |
The median serum testosterone concentration of the patients with a BMI <25 kg/m2 was 5.5 ng/dL. The patients with a BMI of 25-30 kg/m2 had a median serum testosterone concentration of 3.8 ng/dL. Those patients with a BMI >30 kg/m2 had a median concentration of 5.7 ng/dL. No significant difference in the serum testosterone concentrations among the 3 groups was found. The sex hormone-binding globulin levels declined with an increasing BMI. The concentration of free testosterone was significantly greater in the obese men.
Conclusion |
Using an ultrasensitive technique of serum testosterone measurement, the present data have shown that no difference exists in the serum testosterone concentration in the castrate range among normal weight, overweight, and obese patients receiving LHRH agonist therapy for prostate cancer. From our findings and current knowledge, more stringent follow-up or changes in dosage or dosage intervals of LHRH agonist therapy in those with a greater or high BMI is not warranted.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Financial Disclosure: The authors declare that they have no relevant financial interests. |
|
| Funding Support: Tim van der Sluis received an unrestricted educational grant from Astellas Pharma BV. |
Vol 81 - N° 5
P. 1005-1009 - maggio 2013 Ritorno al numero
Articolo precedente
- Editorial Comment
- Rebekah Beach, John T. Wei
- Osteoporosis Management Program Decreases Incidence of Hip Fracture in Patients With Prostate Cancer Receiving Androgen Deprivation Therapy
- Ali-Asghar Zhumkhawala, Joseph M. Gleason, T. Craig Cheetham, Fang Niu, Ronald K. Loo, Richard M. Dell, Steven J. Jacobsen, Gary W. Chien
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?